<img src="https://ml.globenewswire.com/Resource/Download/d0986bd6-4603-4e31-8ed1-f23b3e123605?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Iovance.jpg" alt="Iovance Biotherapeutics, Inc."/>SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, August 6, 2026 at 8:30 a.m. ET to report its second quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at <a href="https://url.us.m.mimecastprotect.com/s/_hgoCZ6DW0iDMKrLSKiwcBlYXS?domain=edge.media-server.com" rel="nofollow" target="_blank" title="">https://edge.media-server.com/mmc/p/3f4w9ts7</a>. The live and archived webcast can be accessed in the Investors section of the Company’s website, <a href="https://ir.iovance.com/" rel="nofollow" target="_blank" title="IR.Iovance.com">IR.Iovance.com</a>. The archived webcast will be available for one year.  About Iovance Biotherapeutics, Inc.  <a href="https://www.iovance.com/" rel="nofollow" target="_blank" title="Iovance Biotherapeutics">Iovance Biotherapeutics</a>, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The <a href="https://www.iovance.com/our-science/til-platform/" rel="nofollow" target="_blank" title="Iovance TIL platform">Iovance TIL platform</a> has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit <a href="http://www.iovance.com" rel="nofollow" target="_blank" title="www.iovance.com">www.iovance.com</a>. Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. CONTACTS Investors <a href="mailto:IR@iovance.com" rel="nofollow" target="_blank" title="IR@iovance.com">IR@iovance.com</a>  650-260-7120 ext. 150 Media <a href="mailto:PR@iovance.com" rel="nofollow" target="_blank" title="PR@iovance.com">PR@iovance.com</a>    650-260-7120 ext. 150 <img alt="" src='https://ml.globenewswire.com/media/MTVlZTMyZjItY2Y1OC00ZDhmLTk3NTItODk0MzVkNDFiNjE5LTEwMzA3NjktMjAyNi0wNy0zMC1lbg==/tiny/Iovance-Biotherapeutics-Inc.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn